Adial Pharma
web2Adial Pharmaceuticals is a clinical-stage biopharmaceutical company developing experimental tre...
About
Adial Pharmaceuticals is a clinical-stage biopharmaceutical company developing experimental treatments for inflammatory diseases, with its lead program targeting ulcerative colitis following the acquisition of Azora Therapeutics. Its AT177 candidate is an oral, colon-targeted drug designed to activate the aryl hydrocarbon receptor locally in the intestine. The program remains in preclinical development, with human studies subject to regulatory authorization. Adial also retains AD04, a genetically targeted candidate for alcohol use disorder, but its regulatory filing states further development depends on dedicated partner or other funding. The company does not have an approved product and finances research through capital raising and other potential arrangements rather than medicine sales.
Explore this sector
Exchange listings
Listing identities only. Orbitrum does not publish live prices or market performance on this public profile.
Adial Pharma profile.
Expert coverage
No published expert evaluations are available for this project yet.
Orbitrum Academy